Breaking News
Diri Care, a Consumer Health Technology Startup, Closes US$4.3 Million in Seed Funding Co-led by East Ventures and Sequoia Capital India & Southeast Asia’s Surge
Diri Care, a consumer health technology startup, today announced it has closed its oversubscribed seed round at US$4.3 million, co-led by East Ventures and Sequoia Capital India and Southeast Asia’s Surge, with follow-on participation from prominent angel investor, Henry Hendrawan.
Diri Care, which literally translates to ‘self-care’ in Bahasa, is an on-demand, one-stop digital clinic for skin, hair and intimate health conditions. Users will be able to receive rapid health assessments by certified physicians, personalized treatment prescriptions, and clinically-proven products delivered to their doorsteps in as fast as two hours.
Diri Care is addressing a dire need in the consumer health industry in Indonesia – starting with beauty and personal care, as the rapidly growing sector is expected to reach US$9.6 billion by 2025. Easy healthcare access is also crucial in a country where there are an estimated 0.4 doctors per 1,000 persons, and residents often have to contend with long wait times, lengthy commutes or costly products and services.
Customers suffering from chronic skin, hair and personal health conditions such as acne, dark spots, skin aging, hair loss, performance anxiety, among others, can now connect to Diri Care’s 24/7 virtual support, as well as receive affordable and efficacy-driven treatments.
“This investment serves as a strong testament towards Diri Care’s mission in revolutionizing consumer healthcare solutions. Diri Care marries technology and medical science to inspire authentic confidence and well-being for modern consumers. We believe everyone deserves affordable, high-quality, patient-centric care, and Diri Care is leading the way in democratizing that access for everyone, everywhere, for good,” said Christian Suwarna, Co-Founder and Chief Executive Officer of Diri Care.
Funding will be channeled into expanding access of Diri Care’s offerings to millions of customers and to further enhance the platform’s technological capability that underpins their results-driven, affordable, and seamless service experience.
“Indonesia has a thriving consumer health market, with 270+ million of population seeking quality and affordable health and well-being solutions. Digital transformation is a key lever that presents enormous opportunities for Indonesia to elevate the quality of our health services sector, and we see Diri Care as a high-performing team that is uniquely well-equipped to integrate its care model with various revolutionary consumer health services and products in one seamless digital platform. We are glad to welcome Diri Care into the East Ventures family, and we fully support Diri Care’s mission to transform the future of care delivery for modern consumers,” said Willson Cuaca, Co-Founder & Managing Partner of East Ventures.
Diri Care launched its beta version of the platform in March 2022, and since then they have recorded more than 13,000 consultations and seen revenues grow by 600%. Diri Care continues to enhance the digital platform by launching its app in both iOS and Android in the near future.
Diri Care was founded by Christian Suwarna, its Co-Founder and Chief Executive Officer; Armand Amadeus, Co-Founder and Chief Operating Officer; and Dr. Deviana Himawan, Co-Founder and Chief Clinical Officer. Previously, Chris was Traveloka Group’s CMO and CEO of their Experience unit. Armand was a Project Leader at the Boston Consulting Group (BCG) in New York, and is also a savvy finance professional with 100+ deals sealed during his time with Goldman Sachs and Baring Private Equity Asia. Devi is a renowned aesthetic and wellness doctor in Jakarta and Diri Care’s clinical officer. Devi helped to build and expand an aesthetic & wellness clinic into a regional brand with 20+ branches across Indonesia, and is highly experienced in product development and aesthetic procedures.
People In This Post
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more